All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for EISAI, INC. · human health care company

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 18, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

HOUSE OF REPRESENTATIVES
SENATE
U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

S 2296
National Defense Authorization Act for Fiscal Year 2026
HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
S 891
Bipartisan Health Care Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 4

Health Issues

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act (S.2296/H.R.3838/P.L.119-60); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; Section 899.

Trade (domestic/foreign)

Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.